| 引用本文: | 石庆芳,杨俊娥,李玲玲,王大庆.ALDH1和CD133表达预测胃腺癌化疗疗效的价值[J].中国现代应用药学,2021,38(20):2586-2590. |
| SHI Qingfang,YANG Jun'e,LI Lingling,WANG Daqing.Value of ALDH1 and CD133 Expression in Predicting the Efficacy of Chemotherapy for Gastric Cancer[J].Chin J Mod Appl Pharm(中国现代应用药学),2021,38(20):2586-2590. |
|
| 摘要: |
| 目的 通过检测乙醛脱氢酶1（acetaldehyde dehydrogenase，ALDH1）和分化簇133（cluster of differentiation 133，CD133）在胃腺癌内的表达情况，探讨其预测胃腺癌化疗疗效的价值。方法 采用免疫组化方法检测2018年3月-2019年5月衡水市人民医院收治的以奥沙利铂为基础行化疗的81例患者胃腺癌组织ALDH1和CD133蛋白表达情况，CT评估化疗疗效，分析ALDH1和CD133蛋白表达与化疗疗效的关系。结果 81例胃腺癌患者疾病进展（progressive disease，PD）28例，疾病稳定（stable disease，SD）38例，部分缓解（partial response，PR）13例，完全缓解（complete response，CR）2例，化疗有效率（SD+PR+CR）65.4%。单因素分析结果显示ALDH1蛋白表达阳性、CD133蛋白表达阳性及分化程度好的患者化疗疗效较ALDH1蛋白阴性、CD133蛋白阴性、分化程度差患者化疗有效率明显较低，差异具有统计学意义（P<0.05），而性别、年龄、病变部位、临床分期及淋巴结转移与胃腺癌化疗疗效无明显相关。多因素分析结果显示ALDH1蛋白和CD133蛋白阳性表达是评估进展期胃腺癌患者化疗疗效的独立预测因素。结论 胃腺癌组织ALDH1和CD133表达可能成为预测胃腺癌化疗疗效的重要分子生物学指标，可为胃腺癌个体化治疗提供参考依据。 |
| 关键词: 胃腺癌 化疗 乙醛脱氢酶1 分化簇133 |
| DOI：10.13748/j.cnki.issn1007-7693.2021.20.020 |
| 分类号:R969.4 |
| 基金项目:河北省医学科学研究重点课题基金资助项目（ZD20140294） |
|
| Value of ALDH1 and CD133 Expression in Predicting the Efficacy of Chemotherapy for Gastric Cancer |
|
SHI Qingfang, YANG Jun'e, LI Lingling, WANG Daqing
|
|
Department of Oncology, Hengshui People'sHospital, Hengshui 053000, China
|
| Abstract: |
| OBJECTIVE To explore the value of aldehyde dehydrogenase 1(ALDH1) protein and cluster of differentiation 133(CD133) protein expression in predicting the efficacy of chemotherapy for gastric cancer. METHODS Immunohistochemical method was used to detect the expression of ALDH1 protein and CD133 protein in 81 patients with gastric cancer who underwent oxaliplatin-based chemotherapy from March 2018 to May 2019 at Hengshui People's Hospital. CT evaluated the efficacy of chemotherapy, analyzed the relationship between clinicopathological features and chemotherapy efficacy. RESULTS There were 28 cases of progressive disease(PD) in 81 cases of gastric cancer, 38 cases of stable disease(SD), 13 cases of partial response(PR), 2 cases of complete response(CR). The yield of total chemotherapy(SD+PR+CR) was 65.4%. Univariate analysis showed that patients with ALDH1 protein positive, CD133 protein positive expression and poor differentiation had poorer chemotherapy efficacy(P<0.05). Gender, age, lesion location, clinical stage and lymph node metastasis were not significantly correlated with chemotherapy efficacy of gastric cancer. Multivariate analysis showed that ALDH1 protein and CD133 protein expression were independent predictors of poor chemotherapy response in patients with advanced gastric cancer. CONCLUSION The positive expression of ALDH1 protein and CD133 protein may be an important molecular biological indicator for predicting the efficacy gastric cancer, which may provide a reference for individualized treatment of gastric cancer. |
| Key words: gastric adenocarcinoma chemotherapy aldehyde dehydrogenase 1 cluster of differentiation 133 |
